臨床研究等提出・公開システム

The effects of dapagliflozin on anemia of chronic kidney disease (Study A)

The effects of dapagliflozin on anemia of chronic kidney disease (Study A)

Hamano Takayuki

Nagoya City University Hospital

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi

hamatea@med.nagoya-cu.ac.jp

Suzuki Kodai

Nagoya City University Hospital

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi

+81-52-858-7429

kodais@med.nagoya-cu.ac.jp

Recruiting

Mar. 08, 2021

Interventional

randomized controlled trial

open(masking not used)

active control

parallel assignment

treatment purpose

(1) Those with CKD stage 3-4 and diabetes mellitus or heart failure with reduced ejection fraction, those with CKD without diabetes or heart failure with reduced ejection fration (eGFR 15-59 mL/min/1.73m2)
(2) Those on erythropoiesis stimulating agents (ESA) or hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors
(3) Those without iron deficiency (transferrin saturation >= 20% or ferritin >= 50 ng/mL)
(4) Those who are not on SGLT2 inhibitors
(5) Those who gave informed consent
(6) Age >= 20 years old at the time of consent (both men and women, and inpatients and outpatients)
(7) For those with heart failure with reduced ejection fraction, they should be on standard therapy for heart failure (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, or beta blockers)

(1) Those with history of allergy to dapagliflozin
(2) Those with severe ketoacidosis, hyperosmolar coma or precoma, or type 1 diabetes
(3) Those with hospitalization due to infection, surgery under general anesthesia, trauma requiring surgical intervention, gastrointestinal bleeding, transfusion, active malignancy within 3 months, or those expecting surgery within 3 months
(4) Those with non-adherence
(5) Pregnant or potentially pregnant women
(6) Those whom treating physicians judge inappropriate candidates for participating in the study

Both

Chronic kidney disease stage 3-4 and anemia of chronic kidney disease

dapagliflozin

Dapagliflozin, diabetes mellitus, chronic kidney disease Anemia of chronic kidney disease, heart failure with reduced ejection fraction

Dapagliflozin, SGLT2 inhibitor

The change in dose of ESA/HIF-PH inhibitors

Hemoglobin, erythropoietin, P, Mg, creatinine, blood pressure, body weight, blood sugar, HbA1c or glucoalbumin, ferittin, transferrin saturation, hepcidin, erythroferrone

+81-52-853-8346

Feb. 19, 2021

No

none